ClinicalTrials.gg
RecruitingNCT05552937Updated Sep 23, 2022

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

A Phase 2 interventional study of Tafasitamab and Lenalidomide in DLBCL, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Sep 2021, registered Sep 2022).
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

02

Conditions studied

  • DLBCL
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years.
  2. confirmed diagnosis of DLBCL not otherwise specified (NOS); T cell/histiocyte rich large B-cell lymphoma (THRLBCL); Epstein-Barr virus (EBV) positive DLBCL of the elderly (EBV-positive DLBCL), Grade 3b Follicular Lymphoma, Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse, according to the Revised European American Lymphoma/World Health Organization (REAL/WHO) classification. Additionally, patients with the evidence of histological transformation to DLBCL from an earlier diagnosis of low grade lymphoma (i.e., an indolent pathology such as follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia) into DLBCL with a subsequent DLBCL relapse are also eligible.
  3. Patients received at least one, but no more than three previous systemic regimens for the treatment of DLBCL and one therapy line must have included a CD20-targeted therapy.
  4. Patients must meet the following laboratory criteria at screening.
  5. Patients must use an effective barrier method of .
  6. In the opinion of the investigator the patients must be able and willing to receive adequate prophylaxis and/or therapy for thromboembolic events; be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and give written acknowledgement of this.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have other histological type of lymphoma,primary DLBCL,a history of "double/triple hit" genetics.
  2. Patients who have, within 14 days prior to Day 1 dosing:

    1. not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, anticancer therapy or other lymphoma specific therapy.
    2. undergone major surgery or suffered from significant traumatic injury.
    3. received .
    4. required parenteral antimicrobial therapy for active, intercurrent infections.
  3. Patients who:

    1. were previously treated with CD19-targeted therapy or IMiDs® (e.g. thalidomide, LEN).
    2. have undergone within the period ≤ 3 months prior to signing the form.
    3. have undergone previous allogenic stem cell transplantation.
    4. have a history of deep venous thrombosis/embolism and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period.
    5. concurrently use other anticancer or experimental treatments.
  4. Prior history of other than DLBCL.
  5. Patients with:

    1. positive and/or C serology.
    2. known seropositivity for or history of active viral infection with (HIV).
    3. CNS lymphoma involvement.
    4. history or evidence of cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromise the patient's ability to give informed consent.
    5. history or evidence of severe hepatic impairment (total serum > 3 mg/dL).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Tafasitamab and Lenalidomide

    Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.

    Drug: Tafasitamab and Lenalidomide

Interventions

  • DrugTafasitamab and Lenalidomide

    Drug pages: TafasitamabStudies of TafasitamabTafasitamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle. Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Evaluation by the Independent Review Committee (IRC).

    Time frame: 1-3 years approximately

Secondary outcomes

  1. Objective Response Rate (ORR)

    Evaluated by the IRC according to cheson 2007 and cheson 2014.

    Time frame: 1-3 years approximately

  2. Disease Control Rate (DCR)

    Time frame: 1-3 years approximately

  3. Duration of Response (DOR)

    Time frame: 1-3 years approximately

  4. Progression Free Survial (PFS)

    Time frame: 1-3 years approximately

  5. Time to progression (TTP)

    Time frame: 1-3 years approximately

  6. Time to response (TTR)

    Time frame: 1-3 years approximately

  7. Overall Survival (OS)

    Time frame: 1-3 years approximately

  8. Safety of Lenalidomide combined with Tafasitamab according to the frequency and severity of adverse events (AEs).

    Time frame: 2 years

  9. Potential immunogenicity of Tafasitamab.

    Time frame: 2 years

  10. Maximum serum concentration (Cmax)

    Time frame: 2 years

  11. Time to maximum serum concentration (tmax)

    Time frame: 2 years

  12. Apparent trough serum concentration before dosing (Cpd)

    Time frame: 2 years

  13. Area under the serum concentration versus time curve from time 0 to the time t of the last quantifiable concentration (AUC0-t)

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • The First Afflicated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Apr 2025, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 23, 2022
StartActual
Sep 6, 2021
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2027
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05552937
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Sep 6, 2021
Primary completion
Apr 2025 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 23, 2022

Study contacts

Huili Zhou
Contact
Yixuelunli123@163.com
86 571-87236685

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tafasitamab · Lenalidomide

Start the discussion